Quality of Life in Pediatric Minimally Invasive Surgery. Cost-Utility Analysis of Laparoscopic Versus Open Appendectomy

2021 ◽  
Author(s):  
Sara Fuentes ◽  
Javier Núñez-Alfonsel ◽  
José-María Pradillos-Serna ◽  
Carme Grande-Moreillo ◽  
Jaume Margarit-Mallol ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Minimally Invasive Surgery ◽  
Minimally Invasive ◽  
Invasive Surgery ◽  
Open Appendectomy ◽  
Cost Utility ◽  
Cost Utility Analysis ◽  
Utility Analysis ◽  
Laparoscopic Versus Open Appendectomy

scholarly journals Rituximab in generalized myasthenia gravis: Clinical, quality of life and cost–utility analysis

2017 ◽  
Vol 2 (3) ◽  
pp. 81-85 ◽  
Author(s):  
João Peres ◽  
Rita Martins ◽  
José Delgado Alves ◽  
Ana Valverde
Keyword(s):  
Quality Of Life ◽  
Myasthenia Gravis ◽  
Cost Utility ◽  
Cost Utility Analysis ◽  
Utility Analysis ◽  
Clinical Quality

scholarly journals Transanal minimally invasive surgery: impact on quality of life and functional outcome

2015 ◽  
Vol 30 (3) ◽  
pp. 1184-1187 ◽  
Author(s):  
Maria Verseveld ◽  
Renée M. Barendse ◽  
Martijn P. Gosselink ◽  
Cornelis Verhoef ◽  
Eelco J. R. de Graaf ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Minimally Invasive Surgery ◽  
Minimally Invasive ◽  
Functional Outcome ◽  
Invasive Surgery ◽  
Transanal Minimally Invasive Surgery

scholarly journals Effects of minimally invasive and traditional surgeries on the quality of life of children with congenital heart disease: a retrospective propensity score-matched study

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Hui Tan ◽  
Erjia Huang ◽  
Xicheng Deng ◽  
Dongping Li ◽  
Shayuan Ouyang
Keyword(s):  
Quality Of Life ◽  
Congenital Heart Disease ◽  
Heart Disease ◽  
Minimally Invasive Surgery ◽  
Propensity Score ◽  
Minimally Invasive ◽  
Invasive Surgery ◽  
Congenital Heart ◽  
Physical Appearance

Abstract Background The focus of clinical care after treating congenital heart disease (CHD) has shifted from saving patients’ lives to improving their quality of life. This study aimed to examine the influence of minimally invasive and traditional surgeries on the quality of life of children with CHD. Methods This was a retrospective cross-sectional study. A total of 459 children aged 2–18 years with CHD treated at Second Xiangya Hospital of Central South University from July 2016 to June 2017 were enrolled, among whom 219 underwent minimally invasive surgery and 240 traditional surgery. The quality of life of children with CHD after surgery was reported by the patients’ parents. We applied propensity score matching to correct for confounding factors and conducted multiple linear regression analysis to examine the related effects of minimally invasive and traditional surgeries on the quality of life of children with CHD. Results The scores of problems related to perceived physical appearance in children undergoing minimally invasive surgery was higher than those in those undergoing traditional surgery (p = 0.004). Different treatment modes were independent influencing factors for problems related to perceived physical appearance in children with CHD. There was no significant difference in average treatment effect scores of children undergoing different surgical procedures in other quality of life dimensions (problems related to cardiac symptoms and their treatment, drug treatment, anxiety regarding treatment, cognitive psychology, and communication), suggesting that different operation modes were not independent influencing factors for these related problems. Conclusion Compared with traditional surgery, minimally invasive surgery can significantly improve the physical appearance perception scores of children with CHD after surgery. Therefore, minimally invasive surgery can improve the quality of life of children with CHD.

scholarly journals Long Term Survival and Quality of Life after Minimally Invasive Surgery for Early Gastric Cancer.

1998 ◽  
Vol 31 (4) ◽  
pp. 1015-1019
Author(s):  
Tetsuro Kubota ◽  
Yoichiro Ishikawa ◽  
Soichiro Isshiki ◽  
Takeyoshi Yokoyama ◽  
Koji Fujita ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Gastric Cancer ◽  
Minimally Invasive Surgery ◽  
Early Gastric Cancer ◽  
Minimally Invasive ◽  
Invasive Surgery ◽  
Term Survival ◽  
Long Term Survival

Change in Quality of Life and Cost/Utility Analysis in Open Stage-related Surgical Treatment of Elbow Stiffness

Orthopedics ◽  
2013 ◽  
Vol 36 (7) ◽  
pp. e923-e930 ◽  
Author(s):  
Giuseppe Giannicola ◽  
Gianluca Bullitta ◽  
Federico M. Sacchetti ◽  
Marco Scacchi ◽  
David Polimanti ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Surgical Treatment ◽  
Cost Utility ◽  
Cost Utility Analysis ◽  
Utility Analysis ◽  
Elbow Stiffness

Health-Related Quality of Life and Cost–Utility Analysis of Employees With Musculoskeletal Disorders Receiving Vocational Physiotherapy

2020 ◽  
Vol 68 (10) ◽  
pp. 476-479
Author(s):  
Laran Chetty
Keyword(s):  
Quality Of Life ◽  
Musculoskeletal Disorders ◽  
Cost Utility ◽  
Cost Utility Analysis ◽  
Health Related Quality ◽  
Utility Analysis ◽  
Related Quality ◽  
Health Related ◽  
The Cost

Background: The purpose of this project was to evaluate both health-related quality of life (HRQoL) and cost-utility associated with care for employees with musculoskeletal disorders who received vocational physiotherapy at a North London National Health Service (NHS) Foundation Trust in the United Kingdom. Methods: A pre- and post-physiotherapy EuroQol 5 Dimension (EQ-5D) questionnaire was administered to employees presenting to the vocational physiotherapy service (VPS) with musculoskeletal disorders. The cost-utility analysis of the physiotherapy service was calculated using cost data provided by VPS billing information and benefits measured using Quality-Adjusted Life Years (QALYs). Findings: Overall, there was a significant improvement in the EQ-5D index from baseline to discharge in all HRQoL domains. The visual analog scale (VAS) improved from a mean of 31.5 (SD = 18.3) at baseline to 73.2 (SD = 18.5) at discharge. A cost-utility analysis indicated that the VPS would continue to be cost-effective until the cost per employee increased by 82.5%. Conclusion/Application to Practice: The project supports integration of vocational physiotherapy services into an occupational health department.

scholarly journals Cost-Utility Analysis of Saxagliptin/Dapagliflozin Versus Gliclazide and Insulin Glargine: Economic Implications of the Outcomes of the CVD-Real Studies I and II

2020 ◽  
Vol 13 ◽  
pp. 117863292092998
Author(s):  
Enrico Torre ◽  
Giacomo Matteo Bruno ◽  
Sergio Di Matteo ◽  
Chiara Martinotti ◽  
Maria Chiara Valentino ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Sensitivity Analysis ◽  
Insulin Glargine ◽  
Annual Cost ◽  
Basal Insulin ◽  
Cost Utility ◽  
Cost Utility Analysis ◽  
Bodyweight Loss ◽  
Utility Analysis

Diabetes treatment cost represents an ever-growing problem. The adoption of new drugs in therapy, although they can guarantee an improvement in patient’s quality of life, can meet obstacles when it involves an increase in costs. We decided to compare the costs and benefits of the new saxagliptin and dapagliflozin combination versus traditional therapies. Bodyweight loss and the sharp reduction in hypoglycemic episodes were the 2 main clinical outcomes that emerged from registered studies of saxagliptin and dapagliflozin compared with the sulfonylureas. These results, combined with the good cardiovascular risk profile, led to develop a cost-utility analysis. We aimed to show the economic value of this new association therapy. We carried out a cost-utility analysis from the Italian National Healthcare System (NHS) perspective, focused on direct costs related to the treatment and management of main diabetes complications. Utility scores adopted have been measured based on the patient’s perception of weight changes. In light of the better durability profile of saxagliptin/dapagliflozin compared with gliclazide, we also considered a simulation scenario to assess the impact on costs of switching to basal insulin, starting from gliclazide and the fixed combination, respectively, and based on the related probabilities to switch. To assess the robustness of the results, a 1-way sensitivity analysis was performed by changing the main parameters by ±20%. Furthermore, the sensitivity of the results was tested considering the addition of a percent discount, because the purchase costs of drugs are usually subject to hidden discounts. We calculated the total direct annual cost per patient of saxagliptin/dapagliflozin versus gliclazide and insulin glargine for patients with type 2 diabetes mellitus not achieving glycemic control on metformin plus saxagliptin alone, dapagliflozin alone, or gliclazide at a lower dosage. Total treatment costs have been obtained adding the direct cost of the drug, needles, glycemic self-monitoring, hypoglycemic events, cardiovascular complications, and effect on consumption of other drugs. The total direct cost of saxagliptin/dapagliflozin fixed dose combination was €414.62 higher than gliclazide (€1.067.72 vs €653.10), and greater than basal insulin, with a difference of €166.99 (€1067.72 vs €900.72). Despite the higher annual direct total cost, the additional cost per quality-adjusted life year (QALY) gained, compared with gliclazide, has been €11 517, and €4639, when compared with insulin glargine in the base-case scenario, and the robustness of the results has been shown in the sensitivity analysis. The results of our cost-utility analysis, expressed as incremental cost-effectiveness ratios, were fully compliant with the threshold adopted for Italy. Then, saxagliptin/dapagliflozin can be considered a cost-effective oral hypoglycemic agent. The positive effect of this drug on the quality of life, induced by the bodyweight loss, has allowed this outcome, despite the higher annual cost per patient, mainly determined by the drug purchase cost.

Comparison of four strategies of follow-up in thyroid cancer patients: A cost-utility analysis

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 6606-6606
Author(s):  
G. de Pouvourville ◽  
I. Borget ◽  
M. Allyn ◽  
M. Schlumberger
Keyword(s):  
Quality Of Life ◽  
Thyroid Cancer ◽  
Diagnostic Accuracy ◽  
Cancer Patients ◽  
Cost Utility ◽  
Cost Utility Analysis ◽  
Whole Body ◽  
Utility Analysis

6606 Background: In thyroid cancer patients, follow-up is designed to detect recurrent disease and consists of neck- ultrasonography (US), thyroglobulin measurement (Tg) and radioiodine whole body scan (WBS). Recent guidelines have restricted the use of WBS to suspicious cases. To insure diagnostic accuracy, follow-up control requires TSH stimulation, either with thyroid hormone withdrawal (THW) or rhTSH, which have demonstrated similar diagnostic accuracy. THW induces significant morbidity associated with hypothyroidism, leading to a decrease in patient quality of life and ability to work, whereas rhTSH is an innovative costly drug that avoids such patient burden. A societal cost-utility analysis was conducted to compare 4 follow-up strategies, combining a method of stimulation (rhTSH or THW) and a testing protocol (US+Tg+WBS or US+Tg alone). Methods: A Markov model was built to describe the follow-up of thyroid cancer patients first treated by thyroidectomy and radioiodine ablation, over 5 years. Estimates for diagnostic accuracy values and recurrence rate were extracted from a French multicenter randomized trial. Costs were computed from the perspective of the society, including medical resources consumed (hospitalisation, rhTSH, tests, treatment of recurrence). The model also incorporated the benefits of rhTSH in terms of quality of life (utility scores derived from SF36) and the reduction in duration and overall cost of sick leave. Results: Among the 753 patients included, 13 patients presented recurrence. rhTSH stimulation resulted in a higher utility score (0.802 vs. 0.637) over the period of stimulation and a reduction of 1083 € of absenteeism costs in active patients. As compared to the THW+Tg+US+WBS strategy, the incremental cost-utility ratios (ICER) showed economic dominance for the rhTSH strategies with ratios of −16,876 and −19,297 €/QALY with and without WBS respectively. The ICER for the strategy THW+US+Tg reached 29,333 €/QALY, as compared to THW+Tg+US+WBS strategy. Conclusions: the recommended strategy combining Tg determination and US after rhTSH stimulation appears the most cost-effective in the follow-up of thyroid cancer patients, as it is the strategy the less costly and associated with improved patient quality of life. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document